Geisinger Health System, Indivumed Team on Personalized Cancer Projects | GenomeWeb

NEW YORK (GenomeWeb) – The Geisinger Health System has struck a partnership with German personalized cancer services company Indivumed to collect and study patient samples and develop targeted treatments, the partners said today.

The agreement will enable Indivumed and Geisinger to collect samples from consenting patients who are already undergoing a surgical tumor resection. The partners will store portions of those tissue, blood, or urine samples at Geisinger via the MyCode repository, and in an Indivumed bank, where they will be analyzed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: intellectual property landscape of CRISPR genome editing, and more.

A researcher has been convicted of conspiring to steal genetically engineered rice, Reuters reports.

Harvard Medical School's George Church says a woolly mammoth-elephant hybrid is only a few years away, according to the New Scientist.

Intel is ending its sponsorship of the International Science and Engineering Fair, the New York Times reports.